184 related articles for article (PubMed ID: 15875083)
21. [Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317].
Yuan JH; He ZM; Yu YH; Chen ZC
Ai Zheng; 2004 Oct; 23(10):1127-33. PubMed ID: 15473921
[TBL] [Abstract][Full Text] [Related]
22. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
23. Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells.
Priebsch A; Rompe F; Tönnies H; Kowalski P; Surowiak P; Stege A; Materna V; Lage H
Oligonucleotides; 2006; 16(3):263-74. PubMed ID: 16978089
[TBL] [Abstract][Full Text] [Related]
24. Modulation of breast cancer resistance protein mediated atypical multidrug resistance using RNA interference delivered by adenovirus.
Li WT; Zhou GY; Wang CL; Guo CH; Song XR; Chi WL
Chin Med J (Engl); 2005 Jul; 118(13):1123-6. PubMed ID: 16098268
[No Abstract] [Full Text] [Related]
25. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
26. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
27. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
28. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.
Kowalski P; Surowiak P; Lage H
Mol Ther; 2005 Apr; 11(4):508-22. PubMed ID: 15771954
[TBL] [Abstract][Full Text] [Related]
29. Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells.
Lemos C; Kathmann I; Giovannetti E; Dekker H; Scheffer GL; Calhau C; Jansen G; Peters GJ
Int J Cancer; 2008 Oct; 123(7):1712-20. PubMed ID: 18623116
[TBL] [Abstract][Full Text] [Related]
30. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
[TBL] [Abstract][Full Text] [Related]
31. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
32. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
[TBL] [Abstract][Full Text] [Related]
33. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
34. Expression and functional analyses of breast cancer resistance protein in lung cancer.
Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
[TBL] [Abstract][Full Text] [Related]
35. Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition.
Ling G; Zhang T; Zhang P; Sun J; He Z
Int J Nanomedicine; 2016; 11():4077-91. PubMed ID: 27601896
[TBL] [Abstract][Full Text] [Related]
36. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
Shepard RL; Cao J; Starling JJ; Dantzig AH
Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
[TBL] [Abstract][Full Text] [Related]
37. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells.
Ma Y; Wink M
Phytother Res; 2010 Jan; 24(1):146-9. PubMed ID: 19548284
[TBL] [Abstract][Full Text] [Related]
38. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
Farabegoli F; Papi A; Bartolini G; Ostan R; Orlandi M
Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.
Elahian F; Kalalinia F; Behravan J
Drug Chem Toxicol; 2010 Apr; 33(2):113-9. PubMed ID: 20307139
[TBL] [Abstract][Full Text] [Related]
40. ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells.
Mirzaei SA; Gholamian Dehkordi N; Ghamghami M; Amiri AH; Dalir Abdolahinia E; Elahian F
Toxicol Appl Pharmacol; 2017 Dec; 337():22-29. PubMed ID: 29079042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
